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ity. ConClusions: FU and MW are common physical therapies for cervical ectopy. 
But the available evidence suggested that FU is more safe and effectiveness than 
MW for treating cervical ectopy and preventing STIs. However, potential publication 
bias and low quality evidence will reduce the reliability of our results. More careful 
designed studies are needed to provide further clarification.
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objeCtives: The cost-effectiveness (CE) of human papillomavirus (HPV) vaccination 
in women pre-sexual debut has been demonstrated in many countries. The aim of 
this study is to estimate the CE of a 3-dose bivalent HPV vaccination at ages 12 to 55 
year in both rural and urban settings in China. Methods: A previously published 
Markov cohort model was adapted to the Chinese setting, simulating the natural 
history of HPV infection and including the effect of screening and HPV vaccination 
over the lifetime of a 100,000 female cohort for ages 12 to 55 in rural and urban 
China. Transition probabilities and utilities were obtained from published literature. 
Cost data were estimated by Delphi panel using health care payers’ perspective. 
Vaccine cost was assumed  Hong Kong listed price. Vaccine efficacy (VE) was based 
on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on inci-
dent HPV. Costs and outcomes were discounted at 3%. Cervical cancer (CC) cases 
and incremental cost-effectiveness ratio (ICER) for vaccination and screening com-
pared with screening alone were estimated for each vaccination age. Reduced VE in 
women post-sexual debut were investigated in scenario analyses. Results: With 
70% vaccination coverage, a reduction of CC cases varying from 585 to 33 in rural and 
691 to 32 in urban were estimated at ages 12 to 55, respectively. Vaccination remains 
CE up to age 23 in rural and age 25 in urban, as the discounted ICERs were lower 
than the current threshold (3×national GDP 2013/capita=20,292USD, 125,723RMB). 
Scenario analyses with lower VE post-sexual debut confirmed the results with age 
20 in rural and 21 in urban to remain CE. ConClusions: HPV vaccination program 
in girls before age 23 in rural and 25 in urban setting was shown to be cost-effective 
strategies for the prevention of CC in China.
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objeCtives: To evaluate the cost-effectiveness of caspofungin versus C-AmB for 
empirical antifungal therapy in patients with neutropenic fever from health care 
provider perspective in Thailand. Methods: A decision-analytic model was used 
to project costs and outcomes of caspofungin versus C-AmB from treatment initia-
tion until hospital discharge. Since there has not been a head-to-head compara-
tive trial, an indirect treatment comparison was developed based on clinical trials 
that used the same 5-end point composite outcomes, including resolution of fever, 
resolution of baseline infection, absence of breakthrough infection, survival and 
no premature discontinuation. Patients were stratified by the presence or absence 
of baseline infection. Discontinuation because of nephrotoxicity or other adverse 
events were included in the model. Efficacy and safety data were based on Walsh 
2004 (Scenario I) and Walsh 1999 (Scenario II). Life expectancy, quality of life, medical 
resource utilization and disease-related costs were obtained from the literatures 
and expert opinion. Drug prices were those published by Ministry of Public Health. 
All costs were expressed in THB 2013 values. Results: Treatment with caspofungin 
increased life expectancy (LY) by 0.87 and 0.58 years, and resulted in additional 0.63 
and 0.41 quality-adjusted life years (QALYS) when compared to C-AmB in Scenario 
I and II, respectively. In the base-case, use of caspofungin was cost saving in both 
scenarios. The results showed that caspofungin is cost-saving as long as the cost 
of treating nephrotoxicity is higher than 316,830 and 299,762 THB for the respective 
scenarios. The incremental cost-effectiveness ratio (ICER) increases if the cost of 
treating nephrotoxicity or the relative rate of nephrotoxicity decreases. Probabilistic 
sensitivity analysis supported the robustness of these findings. ConClusions: 
This is the first cost-effectiveness   of caspofungin as empirical treatment in 
Thailand. Caspofungin is more effective and less costly compared to C-AmB, and 
the use of caspofungin is anticipated to have both budgetary and health benefits.
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objeCtives: To estimate the effects of maternal education and other associ-
ated factors on the immunization propensity for children and adolescents in 
China. Methods: A longitudinal survey (China Health and Nutritional Survey) 
between 1991 and 2006 were used to analyze the relationship between the immu-
nization receipt status and the potential determinants, including children’ char-
acteristics, the household’ characteristics and the community level influences. 
The recommended immunization schedule for persons aged 0 through 18 in 
China is similar to that from Centers for Disease Control and Prevention in the 
U.S. Descriptive statistics were reported for the sample from 9 provinces of China 
in each wave of surveys. Econometric models were constructed with an indicator 
for immunization propensity as the dependent variable (i.e., any immunization 
received by your children during the past 12 months). Independent variables include 
children’s age, gender, whether preventive health care services covered by insur-
ance, their parents’ education level, the household income, transportation time to 
may increase the difficulty of demonstrating cost-effectiveness of a new treat-
ment (NEW).  Conversely, anticipating generic entry for NEW may improve cost-
effectiveness, particularly if initially of high-cost.  The objective of this study was 
to quantify the impact of anticipated PD on reimbursement decision making in 
the Australian context via multi-cohort cost-effectiveness analysis. Methods: A 
two state oncology model was constructed comparing NEW to SOC over 30-years. 
Probability of survival was assumed to be 3-times higher for NEW at 150-times 
the price of SOC. A price function, based on Australian PD statistics, was applied 
to the price of NEW from year 10 to emulate generic entry.  30 cohorts were run 
through the model, each commencing in subsequent years.  ICERs for each cohort 
and an aggregate ICER across all cohorts were calculated.  Whilst no ICER thresh-
old is applied in Australia, $50k/LY was assumed for analysis purposes. Results: 
For individual cohorts, the cost-effectiveness of NEW improved over time.  ICERs 
ranged from $71K/LY for Cohort 1 to $100/LY for Cohort 22 onwards.  The threshold 
was crossed between Cohort 10 and 11.  For all cohorts over 30 years the aggregate 
ICER was $39K/LY, however only 19 cohorts were required over as many years to 
cross the threshold at an ICER of $49K/LY. ConClusions: TTraditional CEA only 
supports funding of NEW from Cohort 11 onward, suggesting a potential 10 year 
delay to access.  Aggregate CEA however supports funding of NEW immediately 
over a time-horizon of 19 or more years.  Clearly future price changes affect CEA of 
new treatments; failure to appropriately account for them may result in delayed 
access to new medications.
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objeCtives: China spent approximately $150 billion US dollars on prescription 
drugs in 2010, accounting for 47% of its annual health expenditures, which has 
attracted worldwide attention. To investigate the causes of rising drug spend-
ing in China, we decomposed drug expenditures to document reasons for this 
event. Methods: Records of 209,758 inpatients were collected from Urban 
Employee Basic Medical Insurance system covering 626 hospitals and 545 health 
care community centers from 2006 to 2010 in Tianjin, China. We found that 264 anti-
infective drug products with 79 ingredients from 16 narrow therapeutic categories 
were calculated using three and six-factor exponential analysis and index-theoret-
ical methodology. In three-factor analysis, drug expenditure was decomposed into 
quantity effect, price effect and therapeutic choice. To further explore underlying 
cause of drug spending soaring, six-factor exponential methodology was applied to 
measure the change and contribution of each dominant. Results: Using exponen-
tial-based decomposition analysis to elucidate important factors driving prescrip-
tion drugs expenditure growth (which increased 163% during five years), we found 
that quantity effect and therapeutic choice increased by 71% and 45% respectively 
and price effect increased by 6% only. Six-factor analysis revealed that 2010 inpatient 
admission volumes increased 76% and this was the most critical spending driver. 
Therapeutic mix and drug mix within the therapeutic choice was the second most 
important factor (36%) and the third (14%) factor among these factors. In contrast, 
pure unit price was a negative factor (declined 10%) with respect to drug expen-
ditures. ConClusions: The selection of more innovative/more expensive drugs 
over older/less expensive therapies dominated drug expenditure growth. Inpatient 
admission patterns and clinical prescription behavior should be a focus of drug 
spending controls. Health providers, insurance agencies, and policy makers can use 
these data to systematically intervene in health care service improvements instead 
of solely focusing on drug price regulations.
INfEctIous dIsEasE outcomEs rEsEarcH studIEs
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bACkgRound: Sexually transmitted infections(STIs) are serious public health prob-
lems and lead to tremendous burden of health and economy worldwide(account 
for 17% of economic loss caused by diseases in developing countries). Cervical 
ectopy is a common risk factor of STIs(including HIV and human papilloma virus 
infections), especially in developing countries. objeCtives: To assess the com-
parative safety and effectiveness of focused ultrasound(FU) and microwave(MW) 
for cervical ectopy. Methods: We searched Chinese Biomedical Literature data-
base (CBM), the Chinese Scientific Journals database (VIP),the China Academic 
Journals Full-text database (CNKI), MEDLINE, EMBASE, and Cochrane Library 
to July 31, 2013. Randomized controlled trials(RCTs) or clinical controlled 
trials(CCTs) were included. Two reviewers independently screened for eligi-
ble studies, extracted data and assessed risk of bias. We assessed the quality of 
included studies using criteria from Cochrane Handbook 5.0.Statistical analysis 
was performed by RevMan 5.02 , a random-effect model was used in this meta-
analysis. Funnel plots and Egger’s regression analyses were used to evaluate 
the publication bias. We used GRADE to summarize the results. Results: We 
included 26 RCTs(n= 10058) and 13 CCTs(n= 6122) both with high risk of bias. 
Meta-analyses indicated: compared with MW: FU reduced the risk of vaginal bleed 
(RCTs:RR= 0.12,95%CI [0.05-0.29]; CCTs:RR= 0.15,95%CI [0.09-0.25]) and vaginal dis-
charge (RCTs:RR= 0.30,95%CI [0.19-0.47];CCTs:RR= 0.45,95%CI [0.25-0.82]); increased 
cure rate (RCTs;RR= 1.07,95%CI [1.02-1.13];CCTs:RR= 1.16,95%CI [1.01-1.32]) and total 
effective rate (RCTs:RR= 1.04,95%CI [1.02-1.07];CCTs:RR= 1.07,95%CI [0.96-1.20]); 
decreased recurrence rate (RCTs;RR= 0.06,95%CI [0.01-0.45];CCTs:RR= 0.11,95%CI 
[0.02-0.67]). Egger’s regression analyses and funnel plots suggested likely publica-
tion bias in the safety studies. All safety and effective indicators were very low qual-
